Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Recent randomized trials have compared the newer antidiabetic agents to treatments involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality in some observational studies with conflicting results. We reviewed the methodology of these observational studies by searching MEDLINE from inception to December 2015 for all studies of the association between sulfonylureas and cardiovascular events or mortality. Each study was appraised with respect to the comparator, the outcome, and study design–related sources of bias. A meta-regression analysis was used to evaluate heterogeneity. A total of 19 studies were identified, of which six had no major design-related biases. Sulfonylureas were associated with an increased risk of cardiovascular events and mortality in five of these studies (relative risks 1.16–1.55). Overall, the 19 studies resulted in 36 relative risks as some studies assessed multiple outcomes or comparators. Of the 36 analyses, metformin was the comparator in 27 (75%) and death was the outcome in 24 (67%). The relative risk was higher by 13% when the comparator was metformin, by 20% when death was the outcome, and by 7% when the studies had design-related biases. The lowest predicted relative risk was for studies with no major bias, comparator other than metformin, and cardiovascular outcome (1.06 [95% CI 0.92–1.23]), whereas the highest was for studies with bias, metformin comparator, and mortality outcome (1.53 [95% CI 1.43–1.65]). In summary, sulfonylureas were associated with an increased risk of cardiovascular events and mortality in the majority of studies with no major design-related biases. Among studies with important biases, the association varied significantly with respect to the comparator, the outcome, and the type of bias. With the introduction of new antidiabetic drugs, the use of appropriate design and analytical tools will provide their more accurate cardiovascular safety assessment in the real-world setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, sulfonylureas which are the second most commonly used antidiabetic drug after metformin, have been shown to be associated with an increased risk of cardiovascular events and mortality [71].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [71]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“For instance, using as comparator thiazolidinediones, which have been associated with an increased risk of cardiovascular events (55), could lead to an underestimation of the association.”
MethodSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708 · cited 1×
“ple, the 1,443 patients excluded because they received insulin some time during follow-up had to be alive at the time that they received the insulin; such exclusions will introduce immortal time bias (56).”
BackgroundSelf-citationHuxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534 · cited 1×
“It is well established that type 2 diabetes is associated with an increased risk of cardiovascular morbidity and mortality (1).”
BackgroundOral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108 · cited 1×
“In addition to the methodological issues described above, it is important to recognize that there are differences in the pharmacodynamic and pharmacokinetic properties of the different sulfonylureas; these may have an impact on their association with cardiovascular outcomes (58).”
Background(1970) · PubMed · Cited by 976
Cited by
Items 101–195 of 195
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 12
“Sulfonylureas are associated with increased risk of hypoglycemia, weight gain, cardiovascular events, and mortality [87, 88].”
BackgroundLambourg, E. J., Fu, E. L., McGurnaghan, S. J., Conway, B. R., Dhaun, N., Grant, C. H., Pearson, E. R., Mark, P. B., Petrie, J. R., Colhoun, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.012 · Cited by 12
“28 It is possible that the extensive use of sulfonylureas may counterbalance the potential cardioprotective benefits of metformin, resulting in a null effect.”
Federici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study
Park, S., Jeong, H. E., Oh, I., Hong, S., Yu, S. H., Lee, C. B., & Shin, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14330 · Cited by 8
“A recent systematic review highlighted that several observational studies evaluating the cardiovascular safety of antidiabetic drugs reported spurious associations as they were subject to the designrelated biases of time-lag or immortal time bias.(37) In our study, we minimized the time-lag bias by comparing DPP-4is w…”
BackgroundShadyab, A. H., Espeland, M. A., Odegaard, A., Manson, J. E., Haring, B., Johnson, K., Chen, Z., Zhang, B., & LaCroix, A. Z. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf095 · Cited by 8
Beta cells to brain cells: The pivotal role of insulin and glucose metabolism in Alzheimer's disease
Schwartz, S. S., Rhea, E. M., Banks, W. A., & Herman, M. E. (2025) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.70008 · Cited by 7
“The use of SUs in the management of diabetes has also been found to increase (rather than decrease) the risk of developing AD, 160,166,167 and should be avoided in patients with, or at risk of, cognitive issues or dementia.”
Eom, Y. R., Joo, H., Chae, S. E., & Je, N. K. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70183 · Cited by 8
Jeon, W. K., Kang, J., Kim, H.-S., & Park, K. W. (2021) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2021.10.2.210 · Cited by 7
RetractedInsight Into the Perioperative Management of Type 2 Diabetes
Zaidi, S. O., Khan, Y., Razak, B. S., & Malik, B. H. (2020) · Cureus · doi:10.7759/cureus.6878 · Cited by 9
“A review of meta-analysis showed that high risk is attached with the use of sulfonylureas in causing hospitalization, congestive cardiac failure, and mortality [25].”
BackgroundSong, X., Cao, Y., Ye, J., Dai, W., Zhang, S., & Ye, S. (2022) · Medicine · doi:10.1097/md.0000000000030668 · Cited by 7
“Also, these drugs have been associated with an increased all-cause mortality and cardiovascular events in adults with type 2 diabetes.[21,22] Therefore, the clinical use rate of sulfonylureas is low, yet sulfonylurea drugs are the preferred choice to treat MODY13.”
BackgroundIslam, N., Reynier, P., Douros, A., Yu, O. H. Y., & Filion, K. B. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15000 · Cited by 8
“In addition, by comparing two classes used as first-line therapy, this approach reduces the possibility of time-lag bias, a severe form of confounding by disease severity.(17)”
BackgroundMethodPatorno, E., Gopalakrishnan, C., Brodovicz, K. G., Meyers, A., Bartels, D. B., Liu, J., Kulldorff, M., & Schneeweiß, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13735 · Cited by 7
“Several non-randomized studies have found these agents to be associated with an increased risk of CV events;(41) this finding remained consistent after studies with major design-related biases were excluded.(42) Nevertheless, residual confounding by some unmeasured characteristics is possible, although it is unlikely…”
ResultRaghavan, S., Liu, W. G., Saxon, D. R., Grunwald, G. K., Maddox, T. M., Reusch, J. E. B., Berkowitz, S. A., & Caplan, L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000516 · Cited by 9
“Head-to-head studies demonstrating better outcomes with metformin than with sulfonylureas could not distinguish whether metformin has beneficial cardiovascular effects or if sulfonylureas have cardiotoxic affects.(8) We did not observe significant differences in mortality between individuals treated with non-sulfonylu…”
BackgroundHyun, J., Park, M. H., Lee, Y. H., Lee, Y., Jeong, S. J., Choi, S. S., Khim, K. W., Eom, H. J., Hur, J., Park, C. Y., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114238 · Cited by 6
Panchal, R., Nguyen, D. T., Ghule, P., Li, N., Giannouchos, T. V., Pan, R. J., BISKUPIAK, J. E., Britton, L., Nohavec, R., Slager, S. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.139 · Cited by 7
Kuang, W., Raven, L. M., & Muir, C. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2307011 · Cited by 7
“…insulin can be considered as an alternative to sulfonylureas for lowering glucose levels in heart transplant recipients, since sulfonylureas are associated with an increased risk of cardiovascular events in T2DM patients and a higher risk of hypoglycemia compared to metformin [24,85,86].”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Saxon, D. R., Rasouli, N., & Eckel, R. H. (2018) · Drugs · doi:10.1007/s40265-017-0857-3 · Cited by 6
“, glyburide causes more hypoglycemia than other secondgeneration sulfonylureas), and the possibility that the harm attributed to sulfonylureas is related to unintended bias in the design and interpretation of trials rather than to a drug class effect [16, 17].”
BackgroundElharram, M., de Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., Raparelli, V., & Pilote, L. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.025 · Cited by 6
Sulfonylureas as second line treatment for type 2 diabetes
McGowan, L. D., & Roumie, C. L. (2018) · BMJ · doi:10.1136/bmj.k3041 · Cited by 8
Hung, A. M., Hackstadt, A. J., Griffin, M. R., Grijalva, C. G., Greevy, R. A., & Roumie, C. L. (2023) · CMAJ Open · doi:10.9778/cmajo.20210207 · Cited by 5
Goh, S., Kosiborod, M., Lam, C. S. P., Cavender, M. A., Kohsaka, S., Norhammar, A., Birkeland, K. I., Holl, R. W., Mauricio, D., Tangri, N., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15092 · Cited by 5
“linagliptin) on major adverse CV events as well as risk of HHF.(1,2) However, head-to-head comparisons for SU versus SGLT2 inhibitors on CV outcomes are generally lacking.”
BackgroundSchwartz, S. S., & Herman, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394805 · Cited by 6
Charbonnel, B. H. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30125-6 · Cited by 5
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5
Precision medicine in KCNJ11 permanent neonatal diabetes
Greeley, S. A. W., Letourneau, L. R., & Philipson, L. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30138-4 · Cited by 5
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0459-7 · Cited by 5
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Chen, X., Li, W. S., Zheng, J.-W., Huang, M., Wang, J., & Wu, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630686 · Cited by 6
Ma, S., Xu, L., Hou, Y., Zhang, W., Cui, Y., & Chen, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1606816 · Cited by 6
Mahmoud, F., Mueller, T., Mullen, A. B., Sainsbury, C. A. R., Rushworth, G. F., & Kurdi, A. B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15584 · Cited by 5
Wu, C., Tsai, Y., Jung, H.-K., Fu, S., Hsiung, C. A., Liu, H., & Lai, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1965 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
for the DPV and DIVE registry initiatives, Hartmann, B., Lanzinger, S., van Mark, G., Wosch, F. J., Durmaz, M., Plaumann, M., Sziegoleit, S., Seufert, J., Holl, R. W., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01409-3 · Cited by 4
Effects of antidiabetic medications on cardiovascular outcomes
Leung, M. S. T., Lin, S. G., Uthayanan, L., & Harky, A. (2020) · Journal of Cardiac Surgery · doi:10.1111/jocs.14709 · Cited by 4
“Longer use of sulfonylureas and biguanides were also associated with increased risk.(23,28) Conversely, thiazolidinediones, namely Rosiglitazone and Pioglitazone, were associated with decreased risk, implying a protective effect.”
BackgroundNew antihyperglycaemic agents and cardiovascular disease: let's be optimistic
Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000524 · Cited by 6
Jeon, W. K., Kang, J., Kim, H.-S., & Park, K. W. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.89 · Cited by 4
Diabetic Control Agents and Their Impact on Cardiac Surgery Patients: A Clinical Overview
O’Neill, P., Leung, M. S. T., Visser, R. A. B., & Harky, A. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420963688 · Cited by 3
WANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 4
Preoperative optimization of diabetes
Stewart, E., & Selzer, A. R. (2021) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000351 · Cited by 3
“Sulfonylureas carry a risk of asymptomatic hypoglycemia(56) and can increase rates of hospitalization, congestive heart failure, and mortality.(57) Compared with sulfonylureas, meglitinides have a relatively benign safety profile and are less likely to cause hypoglycemia but they can lead to weight gain and carry a ri…”
BackgroundThe Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients
Fadah, K., Alashi, A., & Deoker, A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01619-8 · Cited by 4
Cyber Security Awareness, Knowledge and Behavior in the Banking Sector in Jordan
Abulhaija, S., Hattab, S., & Qusef, A. D. (2022) · International Conference on Information and Communication Systems (ICICS) · doi:10.1109/icics55353.2022.9811212 · Cited by 4
“Correlation analysis is used to indicate the relationship among two or more quantitative variables [30] While the multiple regression analysis is used to model this relationship to predict what will happen in a real-world setting [31].”
MethodKurnikowski, A., Werzowa, J. M., Hödlmoser, S., Krenn, S., Paschen, C., Mußnig, S., Tura, A., Harreiter, J., Krebs, M., Song, P. X. ‐., et al. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100860 · Cited by 3
“47,48 Also, the parallel enrollment but consecutive analysis with the ITP-NODAT study publication in 2021 caused a delay in the publication of the present work.”
ResultNakamura, H., Endo, T., & Tsuda, M. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00737 · Cited by 3
Bauduceau, B., & Monnier, L. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30023-9 · Cited by 3
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Cardiovascular outcome trials in type 2 diabetes: A critical analysis
Ashraf, H., & Ahmad, J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.001 · Cited by 3
Pandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
Too good to be true: Are GLP-1 receptor agonists the new metformin?
Kowall, B., Maier, G. A., & Rathmann, W. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108851 · Cited by 2
Effect of statins in preventing hospitalizations for infections: A population study
Policardo, L., Seghieri, G., Gualdani, E., & Franconi, F. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4557 · Cited by 2
“This method, identifying the effective PDD of any single statin, allows, in our opinion, to exclude possible exposure misclassifications which constitute a major limitation of most previous observational studies, while, at the same time, faithfully reproduces what is observed in the real world.(34)”
MethodDiabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires
Bauduceau, B., & Bordier, L. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30390-5 · Cited by 2
Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
Scheen, A. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_32 · Cited by 2
Securite cardiovasculairedes inhibiteurs de la DPP-4 compareea celle des sulfamides hypoglycemiants.
Scheen, A. J. (2018) · ORBi (University of Liège) · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Chen, M., Lin, L.-Y., Hung, T., Lin, T., Li, C., Lin, T., Chen, Y., Liou, J., & Wang, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70157 · Cited by 1
Kim, H., Lee, S. W., Lim, Y., Han, N., Kang, S. H., Byun, Y., & Kim, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333604 · Cited by 2
“Moreover, certain antidiabetic agents may directly affect CVD risk [24–26], further complicating the interpretation of study results.”
Scherbaum, W. A., & Hamann, A. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0356-5 · Cited by 1
O’Brien, H., & Travis, C. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.010 · Cited by 1
Nikolaev, К. Y., Shevela, A. I., Mustafina, S. V., Rymar, O. D., Ovsyannikova, A. K., Zelenskaya, Е. М., Kovaleva, A. Y., & Израйлевна, Л. Г. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050845 · Cited by 3
Modern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus.
Serik, S. A., & Strona, V. I. (2022) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2022.01.069 · Cited by 1
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Talha, K. M., Fonarow, G. C., Virani, S. S., & Butler, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1155 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
(2024) · Jordan Journal of Biological Sciences · doi:10.54319/jjbs/170110 · Cited by 4
“It is also associated with higher mortality rates and cardiovascular events (Azoulay & Suissa, 2017).”
BackgroundMechanisms of cardiovascular protection of non-insulin antidiabetic medications
Avogaro, A. (2018) · Diabetes Mellitus · doi:10.14341/dm9816 · Cited by 1
Ferreira, A. L. A., Bastos, F., Cordeiro, M., & Portugal, J. (2019) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2019.07.021 · Cited by 4
Diabetology & Cardiology: The Future is Now!
Timar, B., & Gaiță, D. I. (2019) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2019-0022 · Cited by 1
“less SUR1 selective derivates of sulphonylurea) increases of the cardiovascular risk [2-4].”
BackgroundNoninsulin Therapy for Diabetes
Maxson, R., & McCoy, E. K. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.005 · Cited by 1
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.11.001 · Cited by 1
Kim, T. N. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.105 · Cited by 1
“대규모 메타분석들에서도 설포닐유레아의 심혈관질환 안전 성 결과는 다소 상이하게 나타났다[17,18].”
Nikolaev, К. Y., Bondareva, K. I., Kovaleva, A. Y., & Израйлевна, Л. Г. (2021) · Patologiya krovoobrashcheniya i kardiokhirurgiya · doi:10.21688/1681-3472-2021-2-27-37 · Cited by 1
de Kort (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190704sk
Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus
Lathia, T. B. (2020) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/jmgims.jmgims_40_19
The modifying effects of adiposity on the cardiovascular safety of sulphonylureas
Suissa, K., Schneeweiß, S., Douros, A., Filion, K. B., Yin, H., Patorno, E., & Azoulay, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14494
“The safety of sulphonylureas has become a contentious issue over the years, with several observational studies reporting an increased risk of cardiovascular events, namely, cardiovascular mortality, associated with use of these drugs compared with other first-line antidiabetic drugs among patients with type 2 diabetes…”
BackgroundSelf-citationPandya, N., & Patel, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-01782-8_38-1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00765-5
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
The evidence behind early aggressive multi-drug treatment in type 2 diabetes
Cersósimo, E., Solis‐Herrera, C., & Triplitt, C. L. (2021) · Trends in Diabetes and Metabolism · doi:10.15761/tdm.1000121 · Cited by 1
Palikhey, A., Karki, M., Shrestha, J., Shrestha, L., Shrivastava, A. K., Yadav, C. K., & Rayamajhi, B. (2022) · Journal of Universal College of Medical Sciences · doi:10.3126/jucms.v10i01.47228
“21-40 6 (12) 4 (8) 41-60 31 (62) 34 (68) Above 60 13 (26) 12 (24)”
Cheema, M. R. S., & Kumar, S. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02061-8 · Cited by 1
“Certain diabetic medications, such as sulphonylureas, are associated with an increased risk of cardiovascular events and mortality [3] as diabetes becomes more prevalent.”
BackgroundTailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
Introduction: Epidemiology, Definitions, and Pathophysiology
Westcott, G. P., & Beaser, R. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_1
Park, S., Jeong, H. E., Oh, I., Hong, S., Yu, S. H., Lee, C. B., & Shin, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077084
“37 However, bias arising from this misclassification is likely to be minimal, as the maximum possible follow-up was 3 years; if any were present, it is likely to have been non-differential between exposure groups.”
BackgroundDiabetes-Induced Cardiomyopathy: Updates in Epidemiology, Prevention, and Management
Adeghate, E. A., Mohsin, S., Amar, A., AlAmry, S., Alotaiba, M. K., Oyeleye, O. A., & Singh, J. (2024) · Cardiology and cardiovascular medicine. · doi:10.5772/intechopen.1006679
Delbaere, J., Deboever, E., Vaes, B., Nobels, F. R. E., Mamouris, P., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.003 · Cited by 1
Mathis, A., Lane, M. T., & Reid, J. M. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241292692
Kulshrestha, A. K., Zala, U., Upadhye, V. J., & Shrivastav, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00003-6
Kennedy, C., Conroy, L., Millar, B., & de Gaetano, M. (2025) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2025.187
Jebastin, S. J., Nanda, N., Sahoo, J., & Yerrabelli, D. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1751_24
“Both Insulin [16] and Glimepiride [21] induce the expression of eNOS, hence increase NO level.”
Lee, S., Zhou, J., Wong, W. T., Liu, T., Wu, W. K. K., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · Figshare · doi:10.6084/m9.figshare.14538954
Xiang, Y., Tang, X., Xiao, Y., Li, X., Huang, G., Zhou, Q., & Zhou, Z. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109269
Pang, J., Bai, T., Bai, X., Jie, X., Li, X., Ren, W., Zhu, Y., Wan, C., Liu, Y., Liu, J., et al. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02195-0
“For example, in diabetic patients with cardiovascular disease, traditional hypoglycemic drugs, while controlling blood sugar, may have adverse effects on the cardiovascular system owing to risks such as hypoglycemia and weight gain [17, 18].”
Kim, M. H., Gil, J. Y., Min, K. H., Kim, J. H., Park, J. H., Park, S., Han, J. M., & Lee, K. E. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261431777
“2,3 The cardiovascular impact of dipeptidyl peptidase-4 (DPP-4) inhibitors varies, with saxagliptin associated with an increased risk of heart failure, whereas sitagliptin and linagliptin demonstrate a more neutral cardiovascular profile.”
DPP-4 inhibitors in current diabetes care: their foundational role in treating to target
Avogaro, A., Fiaccadori, E., & Rizzo, M. R. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113288 · Cited by 1
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Moklesur, M., Islam, M. N., Simon, N. P., Islam, T., Naser, A. Z. M., Hafez, S., & Hasan, R. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104815
Metadata
- Authors
- Azoulay, L., & Suissa, S.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-04-12
- Volume
- 40
- Issue
- 5
- Pages
- 706-714
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2607457744
- Cited by
- 195
- References
- 75
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 26 · 2017: 10
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- sulfonylureas, cardiovascular events, mortality, metformin, bias in observational studies, antidiabetic drugs, cardiovascular safety, type 2 diabetes
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Regression Analysis, Risk Factors, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.